FilingsTodayEncompass Health
At a glance
Encompass Health reported 2025 revenue of $5.94B, up 10.5% from $5.37B in 2024. Over 4 years since 2021 ($4.01B), that is growth of about 10.3% a year. 2025 was the highest revenue year in this period.
In the last 12 months 6 insiders reported 0 open-market purchases and 10 sales ($47.8M). None of the sales were flagged as 10b5-1 plan trades. The largest was a sale of $21.7M by President & CEO Mark J Tarr on Aug 11, 2026.
Encompass Health filed 12 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), material agreement (3), new financial obligation (2) and officer or director change (2). The latest officer or director change was reported on Feb 20, 2026. It reported a material agreement or a completed acquisition or disposal 3 times.
2 of the 20 investors tracked here held Encompass Health at the last quarter end, worth $21.8M combined. It is the largest weight for Renaissance Technologies (0% of its portfolio), followed by Bridgewater Associates (0%). Reduced: Renaissance Technologies and Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $412.2M | $271M | $352M | $455.7M | $566.2M |
| Diluted EPS | $4.11 | $2.70 | $3.47 | $4.46 | $5.54 |
| Dividend per share | $1.12 | $0.86 | $0.60 | $0.64 | $0.72 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined